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Abstract
 .The enzymatic processing of the membrane-bound renal epidermal growth factor precursor proEGF could be an
important step in the control of nephrogenic repair consecutive to kidney insult. The enzyme machinery responsible for that
processing was examined in a cell-free system consisting of renal membranes isolated from kidney homogenates by
differential centrifugation, and incubated in vitro. After a 24-h incubation at 378C, 6–14% of membrane-bound proEGF was
processed and soluble products with EGF immunoreactivity were released. As revealed by HPLC and Western blotting
 .analysis, the products of proEGF proteolysis consisted of 6 kDa EGF the molecular weight of mature EGF and two
polypeptides with molecular weights around 45 kDa. Interestingly the 45 kDa EGF forms, like the 6 kDa EGF, exhibited
mitogenic activity toward growth-arrested NRK-52E renal cell line. The kinetic study of proEGF degradation gave data
 .  .consistent with the 45 kDa product s being processing intermediate s between proEGF and 6 kDa EGF. The enzymatic
 2q 2q.activity responsible for proEGF nicking was inhibited by divalent heavy metal ions Cu or Zn and several protease
 .inhibitors aprotinin, PMSF, leupeptin, soybean trypsin inhibitor , suggesting that proEGF is processed by kallikrein-like
serine proteases present in the membrane preparations. Along with previous studies, the current observations suggest that
renal kallikreins might play a role in renal tubular regeneration by promoting the release of soluble EGF in renal tissue.
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1. Introduction
 .  .Epidermal growth factor EGF is a short 6 kDa
w xsingle chain polypeptide 1 present in most extracel-
lular fluids and secretions, such as saliva, bile, milk
w xand urine 2 . It is synthesized as a high molecular
 .  .weight 140–150 kDa precursor proEGF exhibiting
the structural features of a membrane-anchored pro-
w xtein 3,4 . In rodents, the submaxillary glands and the
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kidneys have been identified as the predominant sites
w xof EGF production 5 . Like the majority of other
growth factors, EGF acts in a paracrine or, perhaps in
some instances, in an autocrine fashion. It exerts its
effects on cellular activity by interacting with cognate
membrane receptors displayed on the surface of tar-
w x  .get cells 6 . The EGF receptor EGFR , a 170 kDa
transmembrane protein, has been found in essentially
every tissue in the body.
EGF can elicit such a variety of biological re-
w xsponses 7 that it is still difficult to clearly delineate
 .its normal physiological function s . Since its initial
w xdiscovery 8 , EGF has been mainly recognized as a
mitogenic and differentiation factor for many cell
types, in particular epithelial cells. Indeed, the major-
ity of cell lines of epithelial origin exhibit mitotic
activity upon EGF exposure and frequently depends
on this growth factor for their growth and survival in
vitro. EGF, or at least EGF-related factors, appears
essential for normal embryogeny, as recently illus-
trated by the severe developmental defects observed
in transgenic knockout mice lacking functional EGFR
w x9 . Besides, a number of animal and clinical studies
have demonstrated that exogenously supplied EGF
 w x .promotes wound healing see 10–13 for review ,
enhances liver regeneration after partial hepatectomy
w x14 and accelerates nephrogenic repair consecutive
w xto ischemic or nephrotoxic injury 15–19 .
In submaxillary glands, proEGF is enzymatically
w xprocessed to generate mature 6 kDa EGF 7,20 . In
contrast, the bulk of EGF which can be recovered
from renal tissue occurs in the precursor form. The
latter has been immunolocalized in distal tubule
w xmembranes 21–23 . Distal tubule cells are also the
major site of EGF synthesis in the kidney, as revealed
by in situ hybridization and demonstration of pre-
w xproEGF mRNA 21 . Therefore, it has been claimed
that renal proEGF simply accumulates in distal tubules
as a membrane-bound protein, and is not normally
w xcleaved into mature EGF 5,24 . However, there is
now ample evidence that it can be released from
distal tubule membranes and converted into smaller
w xmolecular weight forms including 6 kDa EGF 25,26 .
In particular, processing of renal proEGF has been
observed after ischemia-induced acute tubular necro-
sis and could be an essential step in the complex
w xpositive regulation of nephrogenic repair 22 . In this
context, the enzyme system involved in the nicking
of renal EGF precursor is worth to be explored
further.
In the present study, an in vitro cell-free system
was designed to get a better insight into the prote-
olytic processing of renal proEGF by endogenous
enzymes of the kidney tissue.
2. Materials and methods
2.1. Materials
Rabbit anti-rat EGF antiserum was courteously
provided by Dr R.P. Schaudies Walter Reed Army
.Institute of Research, Washington, DC, USA and
checked for its specificity according to Schaudies and
w xSavage 27 . Sheep anti-rabbit IgG antiserum was
obtained from the Laboratory of Hormonology CER
 . w 3 x Marloie Belgium . methyl- H Thymidine 5
. 125  .Cirmmol , I-mouse EGF 66 mCirmg and the
ECL Western Blotting Kit were purchased from
 . Amersham Belgium, Gent Belgium . Trypsin 12 000
. Urmg and soybean trypsin inhibitor 1 mg inhibits
.10 000 U trypsin were supplied by Sigma Chemical
 .Company, St. Louis, MO USA . Cell culture reagents
came from Life Technologiese, Merelbeke Bel-
. gium and Flow Laboratories, Asse-Relegem Bel-
.gium . All other analytical reagents were obtained
from Sigma.
2.2. Methods
2.2.1. Animals and tissue collection
 .Male Wistar rats 200–220 g body wt. were
purchased from a commercial breeding farm Iffa
.Credo, l’Arbresle, France and allowed at least one
week of acclimatation in an animal facility where the
animals received food and tap water ad libitum. The
rats were sacrificed by cervical dislocation under
CO narcosis. The kidneys were immediately ex-2
cised, snap-frozen in liquid nitrogen and stored at
y808C until subcellular fractionation and biochemi-
cal assays.
2.2.2. Preparation of soluble and membrane-enriched
fractions from rat kidneys
Renal soluble and membrane-enriched fractions
were prepared by differential centrifugation accord-
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w xing to Hock and Hollenberg 28 . Whole kidneys
 .approx. 10 g wet wt. were minced and homoge-
 .nized at 48C in 5 vol of 25 mM Tris-HCl pH 7.4 ,
250 mM sucrose using a Brinkmann Polytron appara-
tus equipped with a P-10 grinding probe. All subse-
quent steps of the procedure were conducted at 48C
unless otherwise stated. The homogenate was cen-
trifuged for 10 min at 600=g to remove large debris
and intact cells. The resulting supernatant was spun at
18 000=g for 30 min. The membrane-enriched frac-
tion of the pellet and the supernatant were mixed and
homogenized. The resulting homogenate was ad-
justed to 100 mM in NaCl and 200 mM in MgSO4
and centrifuged at 30 000=g for 40 min. The super-
natant was collected and referred to as the soluble
 .fraction SF . The pellet was suspended in 25 mM
 .Tris-HCl pH 7.4 , centrifuged for 40 min at 20 000
=g and washed twice more in the same conditions.
 .This renal membrane-enriched fraction MEF was
 .suspended in 2 vol of 25 mM Tris-HCl pH 7.4 ,
distributed in 1 ml-aliquots and stored at y808C until
incubation experiments and biochemical analysis.
( )2.2.3. EGF-Radioimmunoassay EGF-RIA
The amount of soluble immunoreactive EGF was
measured by a non equilibrium double antibody ra-
dioimmunoassay, as detailed in a previous publica-
w x tion 29 . Briefly, 100 ml of RIA buffer PBS, pH
.7.4, 0.25% BSA, 0.1% Triton X-100 containing
either standard 6 kDa rat EGF 0.1–10 ngrml; puri-
.fied from rat submaxillary glands or unknown sam-
ples, were incubated 16 h at 48C with 100 ml of
rabbit polyclonal anti-rat EGF antiserum 1:16 000
. 125dilution . After addition of 50 ml I-mouse EGF
 .approx. 20 000 cpm , the mixture was allowed to
stand 3 h at 48C. To precipitate the bound ligand, 500
ml of sheep anti-rabbit IgG antibody covalently linked
to cellulose beads were added and the mixture was
further incubated 2 h at 48C. The suspension was
centrifuged for 15 min at 1000=g, the pellet was
rinsed with 3 ml of RIA buffer and centrifuged again
in the same conditions. The 125I radioactivity associ-
ated with the immunocomplexes was monitored using
a LKB 1275 Compugamma counter. All assays were
run in triplicate.
The amount of membrane-associated EGF
immunoreactivity was determined after treatment of
MEF with Triton X-100 and trypsin. Membrane-en-
riched fractions were homogenized in 25 mM Tris-
 .HCl pH 7.4 , 1% Triton X-100, incubated 20 min at
room temperature and centrifuged at 25 000=g for
30 min at 48C. The solubilized membrane-associated
 .proteins were incubated 1 h with trypsin 50 mgrml
at 378C. The reaction was terminated by addition of
 .soybean trypsin inhibitor 100 mgrml . The samples
were then assayed for EGF immunoreactivity by RIA
as above.
2.2.4. Bio-Gel chromatography
The different molecular forms of EGF present in
soluble and membrane-enriched fractions were char-
acterized by gel filtration on 0.9 =30 cm Bio-Gel
P-10 and 0.9=60 cm Bio-Gel P-100 columns Bio-
.Rad Laboratories, Richmond, CA, USA , respec-
tively. The columns were equilibrated at 48C in 10
 .mM sodium acetate pH 6.9 , 100 mM NaCl and
0.02% sodium azide. Elution was performed at 48C
with the same buffer, the flow rate being 2 mlrh for
the Bio-Gel P-10 column and 3 mlrh for the Bio-Gel
P-100 column. Calibration of the columns was per-
 .  .formed with Blue Dextran V , BSA 67 kDa; V ,0 BSA
 .soybean trypsin inhibitor 20 kDa; V and ratSTI
 .submaxillary gland EGF 6 kDa; V . ColumnsgEGF
eluates were monitored by absorbance at 280 nm
wavelength and 1.5 ml fractions were collected for
EGF radioimmunoassay. Fractions corresponding to
peaks of EGF immunoreactivity were pooled for the
examination of biological activity.
2.2.5. Processing of proEGF in renal membrane
fractions
ProEGF processing in renal membrane fractions
was performed according to the approach of Jørgen-
w xsen et al. 25 . Prior to each experiment, an appropri-
ate amount of frozen membrane-enriched fraction
was rapidly thawed and centrifuged for 20 min at
15 000=g, 48C. The pellet was suspended in 100
 .mM Hepes pH 8.0 and incubated at 378C for differ-
ent periods of time. ProEGF proteolysis was stopped
 .by addition of aprotinin 500 kIUrml at 48C and the
suspension was immediately centrifuged for 20 min
at 15 000=g, 48C. The soluble EGF immunoreactiv-
ity released in the supernatant was measured by RIA.
For the characterization of the soluble EGF im-
munoreactive products either by high-performance
 .liquid chromatography HPLC or by SDS-PAGE,
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the incubation at 378C of the membrane-enriched
fraction was performed in 100 mM ammonium hy-
 .drogen carbonate pH 8.0 , instead of Hepes buffer.
2.2.6. High-performance liquid chromatography
After each given time of incubation, the membrane
preparation was centrifuged for 30 min at 15 000=g,
48C. The supernatant was collected and lyophilized.
The dry residue was suspended in the high-perfor-
mance liquid chromatography mobile phase 100 mM
.phosphate buffer, 100 mM sodium sulfate, pH 6.8
and chromatographed on a TSK-Gel G3000SWXL
column TosoHaas; 7.8=300 mm; particle size: 5
.mm . The sample volume was 100 ml and the flow
rate, 0.5 mlrmin. Column eluates were monitored by
absorbance at 280 nm wavelength. Calibration of the
column was performed with beta-galactosidase 135
.  .kDa; V , BSA 67 kDa; V , soybean trypsinGAL BSA
 . inhibitor 20 kDa; V , cytochrome c 12.4 kDa;STI
.  .V , rat submaxillary gland EGF 6 kDa; VCYT sgEGF
 .and tryptophan 0.2 kDa; V . Half-min. fractionsTRP
were collected and assayed for EGF immunoreactiv-
ity by RIA.
2.2.7. Western blot analysis
Membrane-associated proEGF and the soluble EGF
immunoreactive products released from the mem-
brane-enriched fractions during incubation at 378C
w xwere characterized using Western blot analysis 30 .
The membrane-enriched fraction was homogenized in
 .50 mM phosphate buffer pH 7.4 , 100 mM NaCl,
1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1%
 .SDS in the presence of aprotinin 500 kIUrml , and
centrifuged 25 min at 100 000=g, 48C. The extract
containing solubilized proteins was mixed with 1
volume of SDS sample buffer, heated 3 min at 908C
w xand subjected to 7.5 or 12% T SDS-PAGE 31 . After
electrophoresis, electrotransfer to nitrocellulose mem-
brane was carried out using a semi dry blotting
 .apparatus Biolyon, Dardilly, France . The membrane
was preincubated 3 h at room temperature in 8.7 mM
 .phosphate buffer pH 8.25 , 138 mM NaCl, 0.2%
 .Triton X-100, 5% BSA buffer A to block nonspe-
cific binding, and incubated overnight in buffer A
 .containing rabbit anti-rat EGF antibody 1:5 000 .
The immunoblot was rinsed in buffer A and incu-
bated for 2 h at room temperature in the same buffer
with a peroxidase-labelled donkey anti-rabbit IgG
 .antibody 1:1 000 . Finally, the immunoblot was ex-
tensively washed in buffer A without BSA and bound
peroxidase activity was visualized using ECL West-
ern Blotting Kit.
2.2.8. Measurement of biological acti˝ity
The biological activity of EGF and of the immuno-
logically-related polypeptides separated by Bio-Gel
chromatography was assessed by examining their
effect on the proliferation of cultured NRK-52E nor-
.mal rat kidney, ATCC no. 1571 cells. All culture
studies were performed at 378C in a normal atmo-
sphere, humidified cell incubator. For routine mainte-
nance, cells were grown in 75-cm2 T-flasks in Dul-
 .becco’s Modified Eagle’s Medium DMEM supple-
mented with 20 mM HEPES and 10% fetal calf
 .serum FCS , and containing 100 Urml penicillin,
100 mgrml streptomycin and 0.25 mgrml ampho-
tericin B. Cells were passed once a week, the medium
being renewed 2 days after plating. In these condi-
tions, they grew with a doubling time of 26 h and
reached confluency 9–10 days after plating. For pro-
liferation assays, cells in DMEM, 10% FCS were
seeded at an initial density of 2=104 cellsrcm2 in
 .12-well plates day 0 and the medium was renewed
on day 2. At day 9, DMEM was replaced by
DMEMrF12 serum-free medium supplemented with
30 nM NaSeO and 10 mgrml transferrin. The effect3
of purified EGF or EGF-related products on DNA
synthesis was examined at day 12, by exposing for 26
h the growth-arrested cells to these compounds and
w3 x  .adding H thymidine 1 mCirml 8 h before the end
of exposure. Thymidine incorporation into cell DNA
was stopped by rinsing twice with PBS, followed by
precipitation with ice-cold 10% TCA. The amount of
w3 xH thymidine present in acid-insoluble material was
estimated by scintillation spectrometry after solubi-
lization with 0.2 M NaOH, 2.5% SDS.
2.2.9. Total protein determination
Total protein concentrations were determined with
the Micro BCA Protein Assay Reagent Kit Pierce
.Chemical Company, USA using BSA as a protein
w xstandard 32 . Membrane fractions were homogenized
 .in 25 mM Tris-HCl pH 7.4 , 1% Triton X-100,
incubated for 20 min at room temperature and cen-
trifuged for 30 min at 25 000=g, 48C, to eliminate
detergent-insoluble material. The supernatants con-
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taining the solubilized membrane-associated proteins
were recovered and used for protein assay.
3. Results
3.1. Quantification and characterization of EGF im-
munoreacti˝e species in soluble and membrane-en-
riched fractions from rat kidneys
 .Levels of immunoreactive EGF in soluble SF and
 .membrane-enriched fractions MEF prepared from
rat kidney homogenates were determined by RIA
using a rabbit polyclonal antiserum raised against rat
submaxillary gland 6 kDa EGF, as described in Sec-
tion 2.2. The immunoreactive material contained in
SF generated a displacement curve parallel to that
Fig. 1. EGF immunoreactivity in soluble and membrane-enriched
 .fractions isolated from rat kidney. Soluble SF and membrane-
 .enriched fractions MEF were isolated by differential centrifuga-
 .tion as described in Section 2.2. SF was analyzed as such l .
 .Prior to analysis, MEF’s ’ were homogenized in 25 mM
 .Tris-HCl pH 7.4 containing 1% Triton X-100, incubated for 20
min at room temperature and centrifuged for 30 min at 25 000= g
and 48C to eliminate particulate material. In addition, an aliquot
of the solubilized membrane-associated proteins was digested for
 .  .1 h with trypsin 50 mgrml at 378C B . At the end of the
incubation, trypsin activity was inhibited by the addition of a
2-fold excess of soybean trypsin inhibitor. All samples were
assayed for EGF immunoreactivity by RIA in triplicate as indi-
 .cated in Methods. Six kDa EGF sgEGF purified from rat
 .submaxillary glands was used as a reference v .
obtained with EGF purified from submaxillary glands.
In contrast, this was not the case for the immuno-
reactivity associated with solubilized membrane pro-
 .teins Fig. 1 which, therefore, proved to be nonin-
dentical with 6 kDa EGF. However, trypsin-treated
solubilized proteins in MEF displayed an immuno-
reactivity similar to that of 6 kDa EGF and produced
a displacement curve parallel to the standard curve. It
should be noted that rat submandibular gland 6 kDa
w xEGF itself resists trypsin digestion 26 . In our exper-
  .imental conditions 1 h with trypsin 50 mgrml at
.378C , all the immunoreactivity was released. Indeed,
the increase of trypsin concentration above 50 mgrml
did not modify the level of released EGF-immuno-
reactivity after 1 h of incubation at 378C data not
.shown . Thus, in subsequent experiments solubilized
membrane-associated protein samples were pretreated
with trypsin in order to quantitatively measure by
RIA the EGF precursor in the rat kidney. In these
conditions, the levels of EGF immunoreactivity in
soluble and membrane-enriched fractions were, re-
spectively, 17.6"4.4 and 423.6"23.2 ng EGF
equivalentsrg of kidney wet wt. This confirms that
)96% of EGF immunoreactivity present in the rat
kidney is associated with membranes, or at least with
particular material, as already shown in previous
w xpublications 22,26,29 .
Previous studies have demonstrated multiple forms
w xof biologically active EGF in milk and urine 33,34 .
To characterize the molecular entities with EGF im-
munoreactivity in the rat kidney, SF and MEF were
 .subjected to Bio-Gel chromatography Fig. 2 and
aliquots of the eluates were tested for EGF immuno-
reactivity by RIA. On Bio-Gel P-10, renal SF was
found to contain a unique form of EGF immuno-
reactivity that comigrated with rat submaxillary gland
 .6 kDa EGF Fig. 2A, peak I . After trypsin treatment
of the pooled EGF immunoreactive fractions of peak
I, the profile of EGF immunoreactivity on Bio-Gel
 .P10 did not appear substantially different Fig. 2B .
w xIn agreement with the work of Breyer and Cohen 3
on the mouse kidney, no EGF precursor was detected
in rat renal SF. Therefore, rat renal soluble fraction
only contains the 6 kDa molecular form of EGF
which is trypsin resistant like submaxillary gland 6
kDa EGF.
On the other hand, Bio-Gel P-100 chromatography
of solubilized MEF proteins revealed a single high
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molecular weight EGF immunoreactivite form eluting
 .  .with Vo Mw)100 kDa Fig. 2C, Peak II . Trypsin
treatment of the pooled EGF immunoreactive frac-
tions of peak II gave rise to a single peak of EGF
immunoreactivity on Bio-Gel P10 with an apparent
 .molecular mass of 20 kDa Fig. 2D . This low molec-
 .  .Fig. 2. Bio-Gel chromatography of proteins from rat kidney soluble fraction SF and solubilized membrane-enriched fraction MEF . A.
 .Elution profile of SF 0.5 ml on Bio-Gel P-10. Left ordinate: absorbance at 280 nm, right ordinate: relative level of EGF
immunoreactivity determined by RIA. Fractions 37–48, corresponding to peak I of EGF immunoreactivity, were pooled, lyophilized and
 .suspended in 0.5 ml of 10 mM sodium acetate buffer pH 6.9 . B. Bio-Gel P-10 chromatography of material from peak I after 1-h
treatment with 50 mgrml trypsin at 378C. Proteolysis was stopped by the addition of 100 mgrml soybean trypsin inhibitor. C. Elution
 .  .profile of solubilized MEF 0.5 ml on Bio-Gel P-100. Before applying to column, MEF was homogenized in 25 mM Tris-HCl pH 7.4
containing 1% Triton X-100, incubated for 20 min. at room temperature and centrifuged at 25 000=g for 30 min. to eliminate particulate
material. Fractions 5–13, corresponding to peak II, were pooled, lyophilized and suspended in 0.5 ml 10 mM sodium acetate buffer pH
.  .  .6.9 as described above. D. Bio-Gel P-10 chromatography of material from peaks I B or II v after trypsin treatment as described
above. Material contained in peak I and II were incubated with trypsin in presence of 1% Triton X-100. Calibration of the columns was
 .  .  .performed with Blue Dextran V , BSA V , 65 kDa , soybean trypsin inhibitor V , 20 kDa and 6 kDa EGF purified from rat0 BSA STI
 .submaxillary gland V , 6 kDa .sgEGF
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ular form of EGF co-eluted with 6 kDa EGF from
 .renal SF in the presence of Triton X-100 Fig. 2D ,
suggesting that the only detectable EGF immuno-
reactivity in the trypsin-digested, Triton-solubilized
MEF proteins occurred as 6 kDa EGF. This finding
was consistent with the RIA data. The high molecular
weight form of immunoreactive EGF in renal MEF,
analyzed by SDS-PAGE and immunoblotting, be-
haved as a single component of 140 kDa, an Mr
 .corresponding to that of proEGF Fig. 3I .
3.2. Processing of EGF precursor associated to mem-
brane fractions of rat kidney
w xJørgensen et al. 25 have shown, in renal mem-
brane preparations, the presence of an enzymatic
activity releasing soluble immunoreactive EGF. The
enzymatic processing was both pH- and tem-
perature-dependent.
In our experiments, the incubation of renal mem-
brane-enriched fractions at 378C led to the release of
increasing amounts of soluble EGF immunoreactiv-
ity. Maximum amounts of EGF immunoreactive ma-
terial were recovered in the supernatant 25.6"1.5
.ng EGF equivalentrg kidney wet wt. after 24 h of
incubation. In parallel, a commensurate decrease of
Fig. 3. Immunoblot analysis of solubilized membrane-associated
 .proEGF B and the soluble immunoreactive products released
 .from MEF during incubation at 378C A . Samples were sub-
 .  .jected to SDS-PAGE on 7.5% T I or 15% T II gels, electro-
transferred to nitrocellulose and immunostained using anti-rat
EGF antibodies as described in Section 2.2.
Fig. 4. Release of soluble immunoreactive EGF from membrane-
 .enriched fractions MEF prepared from rat kidney. Isolation of
MEF from rat kidney was achieved as described in Section 2.2.
Frozen MEF preparations were rapidly thawed and centrifuged
for 20 min at 15 000= g, 48C. The pellets were suspended in 100
 .mM Hepes pH 8.0 and incubated for 24 h at 378C. At the end
of incubation, proteolysis of MEF-associated proEGF by endoge-
 . nous enzyme s was stopped by addition of aprotinin 500
.kIUrml at 48C and the mixture was immediately centrifuged for
20 min at 30 000= g, 48C. EGF immunoreactivity released in the
supernatant or remaining associated with the pellet were mea-
 .sured by RIA as described in Section 2.2. A Level of EGF
 .immunoreactivity in MEF before incubation; B Level of EGF
immunoreactivity in insoluble material pelleted after 24-h incuba-
 .tion of MEF at 378C; C Soluble EGF immunoreactivity released
during 24-h incubation of MEF at 378C. Each value represents
the mean"S.D. of triplicate measurements
proEGF associated to MEF was observed from 423.6
"23.2 to 362.1"10.1 ng EGF equivalentsrg kid-
.  .ney wet wt. Fig. 4 .
The soluble material released from MEF incubated
at 378C for different periods of time was fractionated
by HPLC as described in Section 2.2 and assayed for
EGF immunoreactivity by RIA. As shown in Fig. 5A,
soluble EGF immunoreactivity produced during the
incubation eluted as two distinct peaks at apparent
molecular weights of 45 kDa and 6 kDa, respectively,
suggesting that proEGF processing gives rise to two
distinct EGF forms.
The kinetics of release of these two EGF im-
munoreactive entities during the endogenous prote-
olytic processing of membrane-associated proEGF
were clearly different. As can be seen in Fig. 5A, the
peak eluting at a molecular weight of 45 kDa was
already observed after 1 h of incubation at 378C,
( )F. Journe et al.rBiochimica et Biophysica Acta 1357 1997 18–30 25
while the 6 kDa peak could only be detected after 4
h. Moreover, during the incubation at 378C, a pro-
gressive broadening of the 45 kDa peak was ob-
served, suggesting the appearance of two closely
related molecular species with EGF immunoreactiv-
ity. This was confirmed by Western blotting analysis
of the material recovered from the 45 kDa peak
 .obtained by HPLC Fig. 5A , which demonstrated the
presence of two distinct protein bands with molecular
 .weights close to that of albumin Fig. 3II . Taken
altogether, our data show that at 378C proEGF associ-
ated with renal MEF undergoes enzymatic processing
leading to the release of three distinct molecular
entities with EGF immunoreactivity: two EGF forms
with apparent molecular weights around 45 kDa and
a small form of EGF that coelutes with the rat
submaxillary gland 6 kDa EGF.
As shown in Fig. 5B, the 45 kDa EGF forms were
quantitatively converted into the 6 kDa EGF by
treatment with trypsin, indicating that the 45 kDa
 .EGF forms might be intermediate s between proEGF
and the 6 kDa EGF. Like what was observed with
proEGF solubilized from renal membranes, the dis-
placement curves generated by the 45 kDa EGF
forms in a RIA system were not parallel to the
reference curve obtained with purified 6 kDa EGF,
unless the preparation was pretreated with trypsin
 .data not shown .
3.3. Biological acti˝ity of proEGF clea˝age products
The NRK-52E epithelial-like cell line derived from
the rat kidney possesses the EGF receptor and shows
a mitotic response when exposed to this growth
w xfactor in serum-free cultures 35 . Therefore, these
cells appear as a suitable model to test the biological
activity of EGF or EGF-related polypeptides. EGF
immunoreactive products formed during incubation
of renal MEF at 378C were isolated by Bio-Gel P-100
 .chromatography in two peaks of 6 kDa peak L and
Fig. 5. HPLC analysis of products released during processing of membrane-associated proEGF. After incubation of MEF at 378C., the
preparations were centrifuged. Supernatants were separated on a TSK-Gel G3000SWXL and assayed for EGF immunoreactivity as
described in Section 2.2. A. Elution profiles of immunoreactive hydrolysis products after different times of incubation 1 h, v; 2 h, B; 4
.h, ’; 8 h, %; 24 h, l . B. Effect of trypsin on immunoreactive material released during proEGF processing. The soluble fraction of the
 .incubation mixture was chromatographed after 24 h of incubation v . Fractions collected between 19–23 min retention times were
pooled, lyophilized, suspended in water and incubated for 1 h at 378C. in presence of 50 mgrml trypsin. Hydrolysis was stopped by the
 .addition of soybean trypsin inhibitor and the reaction mixture analyzed by HPLC B as indicated above. Calibration of the columns was
 .  .  . performed with beta-galactosidase V , 135 kDa , BSA V , 65 kDa , soybean trypsin inhibitor V , 20 kDa , cytochrome c V ,GAL BSA STI CYT
.  .  .12.4 kDa , 6 kDa EGF purified from rat submaxillary gland V , 6 kDa and tryptophan V , 0.2 kDa .sgEGF TRP
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 .  .45 kDa peak H , respectively Fig. 6, upper panel .
When added to growth-arrested NRK-52E cells, the
material contained in peaks H and L concentration:
.0.7 ngrml equivalent EGF elicited a mitotic re-
 .sponse Fig. 6, lower panel , showing that the EGF
immunoreactive products arising from renal proEGF
processing are endowed with mitogenic activity like
submaxillary gland EGF.
3.4. Effect of hea˝y metal ions and protease in-
hibitors on renal EGF precursor processing
ProEGF synthesized in rat and mouse submaxillary
glands is subjected to an extensive enzymatic pro-
cessing resulting in its conversion into secreted 6 kDa
w xEGF 36 . Six kDa EGF isolated from mouse sub-
maxillary glands is associated with an EGF-binding
w xprotein showing arginine esterase activity 37,38 ,
presumably responsible for the nicking of proEGF. In
this context, it has been demonstrated that some
divalent heavy metal ions exert an inhibitory effect
on the enzymatic activity of the EGF-binding protein
w x37,38 . On the basis of these observations, the poten-
tial effect of heavy metal ions on the enzymatic
release of soluble EGF from renal MEF incubated for
 .24 h at 378C was investigated Table 1 . Renal
proEGF processing was not significantly affected by
calcium, manganese or magnesium ions but was
markedly inhibited by copper and zinc ions, which
have also been shown to interfere with proEGF pro-
cessing in mouse submaxillary glands.
In order to better define the properties of the
endogenous enzymatic activity responsible for the
processing of membrane-bound proEGF, the effect of
 .various protease inhibitors were tested Table 1 . The
release of soluble EGF immunoreactive material was
sizeably reduced when membrane fractions were in-
cubated 24 h at 378C in the presence of serine
protease inhibitors such as aprotinin and PMSF. A
similar inhibition was observed using leupeptin and
soybean trypsin inhibitor, suggesting that the enzy-
matic system responsible for renal proEGF process-
ing exhibits a trypsin-like activity. The action of
TLCK, another trypsin inhibitor, was also tested but
the answer was not clear after a 24 h incubation at
378C. Finally, the chymotrypsin inhibitor TPCK and
the metalloprotease inhibitors EDTA and EGTA did
not inhibit the release of EGF immunoreactive mate-
rial from renal membranes. These observations lead
 .  .us to postulate that an endogenous serine protease s
Fig. 6. Mitogenic activity of the immunoreactive material re-
leased during incubation of renal membrane-enriched fractions
 .MEF . MEF isolated from rat kidney was incubated for 24 h at
 .378C in 100 mM ammonium hydrogen carbonate pH 8 . At the
end of incubation, particulate material was eliminated by a
30-min centrifugation at 25 000= g and 3 ml of supernatant were
subjected to Bio-Gel P-100 chromatography as described in
Section 2.2. Upper panel, elution profile of EGF immunoreactiv-
ity, as determined by RIA. Fractions 10–18 and fractions 35–43
 . corresponding to high- peak H and low-molecular weight peak
.L immunoreactive material, respectively, were pooled,
lyophilized, suspended in 2 ml of culture medium and assayed for
mitogenic activity on growth-arrested NRK-52E cells in serum-
free culture, as described in Section 2.2. Lower panel, effect of
w3 xEGF and products with EGF immunoreactivity on H thymidine
incorporation into DNA of cultured cells. A. Reference curve
constructed by measuring the cell response in presence of in-
creasing concentrations of purified rat sgEGF. Values are ex-
pressed relative to cells cultured in absence of added EGF. B.
w3 xEffect of material contained in peaks H and L on H thymidine
w3 xincorporation. Cont, baseline level of H thymidine incorpora-
tion in absence of exogenous EGF or EGF related products. Each
 .value is the mean of 3 determinations "S.D. .
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Table 1
Effect of various additives on proEGF processing in rat kidney
membrane-enriched fractions incubated for 24 h at 378C




Control – – 100"20
2qCa – 1 mM 97"11
2qMn – 0.2 mM 93"6
2qMg – 1 mM 101"9
2q )Cu – 0.2 mM 47"3
2q )Zn – 0.2 mM 49"20
)Aprotinin Serine proteases 800 kIUrml 18"2
)PMSF Serine proteases 8 mM 48"4
)Leupeptin Trypsin 0.4 mM 30"6
)Soybean Trypsin 10 mM 37"7
trypsin
inhibitor
TPCK Chymotrypsin 200 mM 99"17
EDTA Metalloproteases 40 mM 90"7
EGTA Metalloproteases 40 mM 95"18
a Amounts of EGF released in supernatants were calculated rela-
tive to controls incubated in absence of ions or inhibitors. Each
value represents the mean"S.D. of triplicate measurements.
) Student’s t-test, P -0.05. PMSF: phenylmethylsulfonyl fluo-
ride; TPCK: L-1-4-tosylamino-2-phenylethyl chloromethyl ke-
tone; EDTA: ethylenediaminetetraacetic acid, disodium salt dihy-
 .drate; EGTA: ethylenebis oxyethylenenitrilo tetraacetic acid.
 .with trypsin-like activity is are involved in the
proteolytic cleavage of the renal EGF precursor.
4. Discussion
In the normal rat kidney, the EGF precursor is
present along the distal convoluted tubule and in the
medullary thick ascending limb of Henle’s loop while
the EGF receptor is mostly located in proximal tubules
w xand collecting ducts 21,23,39–42 . The fact that
proEGF and EGF receptors do not colocalize in renal
tissue points to a paracrine, rather than an autocrine
or juxtacrine system of EGF signalling in the kidney.
Such an assumption automatically entails that mem-
brane-bound high-molecular weight EGF must be
converted into soluble, diffusible EGF. In this re-
spect, it is worth noting the previous studies of
w x w xSchaudies et al. 22 and Schaudies and Johnson 26
which strongly suggest that proEGF undergoes prote-
olytic processing during postischemia nephrogenic
repair.
Previous attempts to characterize the nicking of
renal high-molecular weight proEGF focused on uri-
nary EGF. Fairly high levels of EGF are excreted in
urine, and a number of observations indicate that
most, if not all urinary EGF derives from the precur-
 w x .sor synthesized in the kidney see 43 for review .
Analysis of urinary EGF by the group of Nexø et al.
w x34 revealed two EGF-immunoreactive species, a
 .low-molecular weight form 6 kDa , C-terminally
extended by three residues compared to rat submaxil-
lary gland EGF, and a high-molecular weight form
 .45 kDa , N-terminally extended by approximately
140 amino acids compared to submaxillary gland
w xEGF. In a subsequent study, Jørgensen et al. 25
showed that cell membranes isolated from kidney
tissue homogenate and incubated in vitro release
soluble EGF-immunoreactive products similar, if not
identical to those found in urine. Interestingly, both
in vitro processing of renal membrane proEGF and in
vivo excretion of EGF in urine can be inhibited by
w xaprotinin, a serine protease inhibitor 25,44 .
Using an in vitro assay entirely based on kidney
membrane-enriched fractions, the present study ex-
 .pands previous observations by showing: i the solu-
 .ble fraction SF from the rat kidney homogenate
contains essentially the 6 kDa EGF while the mem-
brane-enriched fraction displays only the 140 kDa
EGF precursor which, solubilized and treated with
trypsin, releases the 6 kDa growth factor; this trypsin
treatment of solubilized proEGF made feasible the
quantitative determination of the EGF precursor in
terms of EGF equivalents, using an anti-6 kDa EGF
 .antibody, ii the in vitro membrane-bound proEGF
enzymatic processing, analyzed by HPLC, leads to
the progressive release of three distinct soluble EGF-
immunoreactive products, i.e. two entities with Mr
values around 45 kDa and a third one with an M ofr
6 kDa, similar to that of mature EGF. The latter
product can be produced from the formers by trypsin
treatment which, once again, allowed the quantitative
determination of the 45 kDa species in terms of EGF
equivalents. The kinetics of appearance of these prod-
ucts during the incubation appeared clearly different,
the 45 kDa products being released largely before the
6 kDa product. These data indicate that the 45 kDa
entities might be molecular forms intermediate be-
 .tween proEGF and the 6 kDa EGF, iii the release of
the three soluble EGF-immunoreactive species is as-
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sociated to a concomitant significant decrease in
 .proEGF after 24 h incubation at 378C, iv the soluble
EGF-immunoreactive products exhibit mitogenic ac-
 .tivity toward growth-arrested NRK-52E cells, v the
endogenous enzymatic activity responsible for
proEGF processing is sensitive to Cu2q and Zn2q,
and also to protease inhibitors such as aprotinin,
PMSF, leupeptin and soybean trypsin inhibitor. Taken
altogether, these observations suggest the existence of
two or more proteolytic enzymes involved in the
processing of membrane-anchored proEGF. The sen-
sitivity profile of these enzymes to a panel of in-
hibitors, as well as the nature of the cleavage sites at
the N- and C-termini of mature EGF, suggest that
they are trypsin-like serine proteases, probably of the
kallikrein type.
Kallikrein-like enzymes form a group of prote-
olytic enzymes participating to physiological pro-
cesses as crucial as blood clotting and thrombolysis.
These enzymes are widely distributed throughout the
organism, and are produced in several organs, includ-
ing those where EGF is synthesized. There is grow-
ing evidence that tissue kallikrein-like enzymes are
responsible for the enzymatic processing of proEGF.
Indeed these enzymes are particularly abundant in the
submandibular gland, a major site of EGF production
w xand secretion in the rat 20 . The mammary gland is
another tissue where proEGF is synthesized and
cleaved to generate soluble EGF. Using RT-PCR-
mediated amplification of cDNA with selected
w xprimers, Jahnke et al. 45 have identified in the
mammary gland of lactating mice a mRNA for mGK-
6, a form of kallikrein which is also found in renal
tissue. Immunostaining with a polyclonal anti-kal-
likrein antiserum revealed the presence of the corre-
sponding protein on the lumenal membrane of alveo-
lar cells. Strikingly enough, cell membranes isolated
from mammary glands and incubated in vitro release
an EGF-immunoreactive product undistinguishable
from salivary gland small-molecular weight EGF.
In the rat kidney, in situ hybridization demon-
strates the presence of kallikrein mRNA in distal
w xconvoluted tubules 46 . Kallikrein gene expression
has also been reported in distal tubules of injured
w xhuman kidneys 47 . As shown by immunohistochem-
ical staining, kallikrein itself has, along the nephron,
a distribution parallel to that of the mRNA, i.e. in
distal tubules, with the exception of the macula densa.
Moreover kallikrein immunoreactivity is mostly pres-
ent on apical membranes. From this colocalization of
kallikrein and proEGF, it is tempting to assume that
the release of EGF in soluble form, such as that
described in the present study, results from a process-
 .ing of proEGF by membrane-bound kallikrein s .
w xRecently, Rogers et al. 48 have shown that the
release of soluble EGF from proEGF-containing renal
membrane preparations occurs at a faster rate when
the membranes are isolated from postischemic kid-
neys, as compared to intact kidneys. Moreover tri-
 .iodothyronin T3 , which is known to promote recov-
ery of renal function after acute ischemic or nephro-
toxic injury, also enhances the in vitro conversion of
membrane-bound EGF into soluble EGF. These ob-
servations lend further support to the fact that the
conversion of proEGF is involved in nephrogenic
repair subsequent to renal insult.
Under normal circumstances, the putative
kallikrein-mediated processing of proEGF in distal
tubules would most probably release 6 kDa EGF and
EGF-related products in tubular fluid, thus account-
ing for the excretion of fairly large amounts of EGF
in urine. The physiological significance of soluble
EGF occurring in tubular lumen remains to be found,
inasmuch as EGF receptors are mostly located at the
contraluminal side of tubular cells. As already noted
above, EGF is likely to be functionally more impor-
tant in the damaged kidney, given the fact that it
contributes with other factors to nephrogenic repair
subsequent to renal tissue injury. Regenerative hyper-
plasia following ischemic or nephrotoxic insult is
accompanied by an abrupt decrease of urinary EGF
w x49 and by a marked elevation of soluble EGF in
w xrenal tissue 22,26,48,50 . Increase of soluble EGF is
matched by a commensurate decrease of membrane-
bound proEGF, and is most probably due to an
enzymatic processing of the latter. The fall in EGF
excretion after kidney insult suggests that soluble
EGF is released in kidney interstitial tissue and no
more in tubular lumen, and could be involved in a
paracrine stimulation of tubular regeneration. Consis-
tent with this view, EGF modifications are accompa-
nied by changes in EGF receptor binding and im-
w xmunoreactivity in proximal tubules 42 . These obser-
vations suggest a modulation of the enzyme machin-
ery involved in renal EGF processing, possibly result-
ing in a relocalization of membrane proEGFrkal-
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likrein within distal tubule cells andror in the expres-
sion of different kallikrein-like enzymes. Since the
mechanism of this reaction of the kidney to injury
will undoubtedly be difficult to investigate in vivo,
the in vitro model described here might prove to be
useful to conduct further exploration at the molecular
level.
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